Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGE058)

• Drug Name: Cabiralizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DMGE058

Molecule-Related Drug Atlas

Drug(s) Targeting Macrophage colony-stimulating factor 1 receptor (CSF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[3]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[1]
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[1]
AMB-05X	DM958C5	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[4]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[5]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[1]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

Drug(s) Targeting Granulocyte-macrophage colony-stimulating factor (CSF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talimogene Laherparepvec	DMKBW5C	Melanoma	2C30	Approved	[8]
Lenzilumab	DMSRIT4	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3 Trial	[2]
JX-594	DM5WCV4	Hepatocellular carcinoma	2C12.02	Phase 3	[9]
Mavrilimumab	DMMVFRC	Rheumatoid arthritis	FA20	Phase 2	[10]
KB002/003	DM60G5O	Rheumatoid arthritis	FA20	Phase 2	[11]
GSK3196165	DMEXKF4	Rheumatoid arthritis	FA20	Phase 2	[10]
KB-003	DM74KIM	Severe asthma	CA23	Phase 2	[12]
MT203	DM7I0MT	Plaque psoriasis	EA90.0	Phase 2	[13]
MORAb-022	DMM7TBO	Autoimmune diabetes	5A10	Phase 1	[14]
Autologous melanoma cell vaccine	DMARYFK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte-macrophage colony-stimulating factor (CSF2)	TTNYZG2	CSF2_HUMAN	Antagonist	[2]
Macrophage colony-stimulating factor 1 receptor (CSF1R)	TT7MRDV	CSF1R_HUMAN	Antagonist	[2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Clinical pipeline report, company report or official report of AmMax Bio
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [7] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [12] US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
• [13] GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
• [14] Clinical pipeline report, company report or official report of Morphotek.